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ABSTRACT 
 
INTRODUCTION:   While animal studies consistently show a preventive role of 
statin use in colon cancer development, evidence from human studies is conflicting 
with recent reports suggesting an increased risk of aberrant crypt foci and 
adenoma. We hypothesize that insufficient control of confounding due to indication 
bias for prescribing of statins, particularly obesity-induced physiologic 
dysregulation, might partly explain discrepant results.   METHODS:   We analyzed 
data from patients receiving standard colonoscopy at the Colon Cancer Prevention 
Program of the University of Connecticut Health Center, which was followed by 
chromoendoscopy for ACF detection.  ACF number was categorized at low (<10) or 
high (≥10).  We calculated Univariate, Age-Adjusted and Multivariate Logistic 
Regression to estimate Odds Ratios (ORs) and 95% Confidence Intervals (CIs) for 
high ACF number in relation to regular statin use (i.e., ≥ 1 pill per week for the past 
12 months). Adiposity measures of Body Mass Index (BMI), Waist-Hip-Ratio 
(WHR) and Waist Circumference (WC) were added separately in the multivariate 
model as surrogates to assess indication bias.  A composite variable was created 
to assess the impact of individual compared to joint regular use of statins and 
aspirin (baby and/or full dose) on ACF number.   RESULTS:   Participants who 
reported regular use of statins had a higher mean ACF number than participants 
who reported taking <1 pill per week (17.20 vs. 9.02, respectively, p=0.001).  The 
mean age for the high ACF group was greater than the mean age for the low ACF 
group (59.40 versus 54.17 years, respectively, p=0.002).  Never and past smokers 
were more likely to have low ACF than current smokers (58.9% vs. 60.0% vs. 
18.2%, respectively, p=0.037).  Univariate logistic regression showed that patients 
who regularly took statins were 3.9 (95%CI=1.43-10.74) times more likely to have a 
high ACF count than those not taking statins regularly, which was reduced to 2.67 
(95%CI=0.89-7.97) in the age-adjusted analysis.  In the basic multivariate model, 
the OR for high ACF among regular statin users was 1.47 (95%CI=0.28-7.74) in 
comparison to patients who consumed 1 or fewer pills per week.  When adiposity 
measures were added into the basic multivariate model, the ORs for high ACF 
were: 1.24 for BMI (95%CI=0.21-7.47; p=0.017); 0.68 for WHR (95%CI=0.10-5.40; 
p=0.702); and 1.20 for WC (95%CI=0.20-1.20; p=0.842).  Compared to taking 
neither aspirin nor statins (referent group), univariate ORs were: 15.0 
(95%CI=1.55-145.23) for taking statins only on a regular basis; 1.83 (95%CI=0.59-
5.68) for regular use of aspirin only; and 4.29 (95%CI=1.24-14.83) for regular use 
of both statins and aspirin.  OR estimates were slightly attenuated in age-adjusted 
analyses and were substantially reduced in multivariate analyses, and no longer 
statistically significant.   CONCLUSIONS:   While regular statin use in our study 
population was associated with a statistically significant higher ACF count in 
univariate analyses, this effect did not remain after controlling for key risk factors 
for colon cancer.  It is possible that prior evidence of an adverse role of statin use 
in colorectal neoplasia in human studies may be explained in part by confounding.  
Our results must be interpreted with caution due to small numbers in study groups.  
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1.0 INTRODUCTION 
 
1.1 Established Risk Factors for Colorectal Cancer 
 
Colorectal cancer (CRC) is the second leading cause of cancer-related 
mortality for both men and women in the United States with over 50,000 deaths 
reported in 2007 alone (CDC, 2012). Incidence rates of CRC in the United 
States, however, have been decreasing recently in both males and females 
(Jemal et al., 2011), over the past two decades, largely due to detection and 
removal of precancerous lesions through CRC screening.   
Regular use of aspirin and other non-steroidal anti-inflammatory drugs 
(NSAIDs) has been reported to reduce the primary occurrence of adenomas 
and contribute to their regression (Stevens et al., 2006).  Regular aspirin use 
has been associated with a reduced risk of CRC as well (Potter, 1999).  Two 
proposed mechanisms linking CRC pathogenesis are insulin resistance and 
chronic inflammation (Bruce et al., 2000; Kaaks et al., 2000; Potter, 1999; 
Stevens et al., 2006).  Adiposity-induced insulin resistance is thought to be the 
pathway linking surplus body fat with colon cancer risk (Swede et al., 2009).  A 
study by Swede et al. (2009) found that a relatively high level of visceral fat 
was associated with increased ACF. Together, this, and the chronic 
inflammation model provide a framework from which a large portion of CRC 
etiology and epidemiology can be interpreted (Stevens et al., 2006).  
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Modifiable risk factors for CRC also include smoking, physical inactivity, 
and dietary intake (Jemal et al., 2011).  Diet is thought to influence 70-90% of 
CRC (Lipkin et al., 1999).  While the mechanism through which diet influences 
CRC is not well understood, it is thought that the increased consumption of red 
meat, and possibility the low intake of fiber, including fruits and vegetables, 
increases CRC risk (Stevens et al., 2006).  Additionally, lack of physical activity 
and obesity are associated with increased risk of CRC (Stevens et al., 2006).   
 
1.2 Statins and Colorectal Cancer: Unclear Evidence     
 
As noted above, anti-inflammatory agents, such as aspirin, are thought to be 
preventive for CRC and possibly ACF.  Another class of drugs, statins, has 
been examined for a possible preventive role in CRC but human evidence 
remains inconsistent.  Statins, which are HMG-CoA inhibitors, are among the 
most commonly prescribed drugs worldwide for their cholesterol-lowering 
properties (Boudreau et al, 2010).  Their use has dramatically risen in the past 
decade and is likely to continue rising (Boudreau et al., 2010).  It is estimated 
that 1 out of every 10 adults in the U.S. population is on statins to reduce 
circulating lipoprotein levels and to consequently decrease their risk for 
cardiovascular disease (Ahnen & Byers, 2009).  There are currently six statins 
on the U.S. market: lovastatin, pravastatin, simvastatin, fluvastatin, 
atorvastatin, and rosuvastatin.   
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Statins inhibit HMG-CoA reductase, a major rate-limiting enzyme of the 
mevalonate pathway, thereby preventing the conversion of HMG-CoA to 
mevalonate (Boudreau et al., 2010).  This results in decreased levels of 
mevalonate and its subsequent products (Boudreau et al., 2010).  Many 
products of the mevalonate pathway are vital for proper cellular functions, 
including membrane integrity, cell signaling, protein synthesis, and cell cycle 
progression (Boudreau et al., 2010).  Inhibition of the mevalonate pathway may 
disrupt these processes in neoplastic cells, resulting in control of tumor 
initiation, growth, and metastasis (Boudreau et al., 2010).  Statins have many 
biologically plausible effects on cancer risk (Ahnen & Byers, 2009) from 
affecting protein synthesis to angiogenesis, apoptosis, cellular immunity, and 
cancer metastasis (Ahnen & Byers, 2009).  Many studies demonstrate statin-
induced programmed cell death, or apoptosis, in several cell lines, including 
mammary carcinoma, lung, colorectal, pancreatic, and prostrate carcinoma 
(Boudreau et al., 2010).   
The initial evidence of a role in CRC came from animal studies, which 
suggested that statins could have chemopreventive properties (Agarwal et al., 
1999).  Epidemiological studies have also suggested that statins play a role in 
CRC.  For example, two large randomized control trials showed decreases in 
the risk for CRC among those randomized to take statins by 19% and 43% 
(Ahnen & Byers, 2009).  These reductions were not statistically significant, 
however, and were secondary endpoints in trials originally conducted for other 
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purposes (Ahnen & Byers, 2009).  Nevertheless, this paved way for a large 
number of observational case-control and cohort studies examining the 
relationship between statins and CRC (Ahnen & Byers, 2009).       
Several case-control and cohort studies have found no association 
between statin use and CRC risk, while two large observational studies 
reported a 35-43% reduction in CRC among statin users compared to non-
users (Boudreau et al., 2010).  In a population-based cohort study, Singh et al. 
assessed the effect of the long-term regular use of statins on the risk of CRC 
(2009).  They reported no statistically significant reduction in CRC risk with 
regular use of statins, irrespective of the duration or dose (Singh et al., 2008).  
Singh et al. also found a small increased risk of CRC associated with low dose 
statin use (Singh et al., 2008).  Statins have been shown to have a stimulatory 
effect on some CRC cell lines (Singh et al., 2008).  
 In a cohort of male veterans undergoing surveillance colonoscopy, 
Parker-Ray et al. (2010) reported that statin use did not decrease the risk for or 
number of adenomatous polyps.  The number of polyps that were found on the 
index colonoscopy was the only factor that was associated with adenoma 
recurrence (Parker-Ray et al., 2010).  Age, BMI, and number of polyps 
detected at index colonoscopy were found to be positively associated with the 
number of polyps detected at follow-up colonoscopy (Parker-Ray et al., 2010).  
Diabetes and non-Hispanic white race was found to be inversely associated 
with the number of polyps detected at follow-up colonoscopy (Parker-Ray et 
  
  
 
 
 
5
al., 2010).  The use of statins was not protective against the recurrence of 
adenomatous polyps (Parker-Ray et al., 2010).  Currently, there is no 
convincing evidence to support prescribing statins for the chemoprevention of 
colorectal neoplasia.  
 
1.3 Aberrant Crypt Foci   
  
Colonic intestinal epithelium is rapidly renewing tissue, due to the loss of cells 
during the final stage of the digestive process, which is marked by homeostatic 
equilibrium between cellular proliferation and abatement (Lopez-Ceron & 
Pellise, 2011).  Aberrant crypt foci (ACF) are pre-polyp abnormalities identified 
in single crypts detected by high magnification chromendoscopy (Stevens et 
al., 2006) using dye (e.g., indigo carmine).  ACF consist of large, thick crypts in 
the colon, first identified in mice treated with azoxymethane (Bird, 1987).  ACF 
were also reported in the colonic mucosa of humans (Takayama et al., 1998).  
Histologically, ACF can be classified as hyperplastic or dysplastic 
(Lopez-Ceron & Pellise, 2011).  Hyperplastic ACF are the most common type 
and consist of larger and longer crypts with apical branching and serration 
(Lopez-Ceron & Pellise, 2011).  Dysplastic ACF are less common, but are 
more frequent in Eastern than Western populations and are composed of 
smaller, non-serrated crypts (Lopez-Ceron & Pellise, 2011).  In most instances, 
ACF are defined as a cluster of crypts that stain darker than their surrounding 
  
  
 
 
 
6
mucosa in addition to one of the following characteristics: crypts with larger 
diameters than surrounding mucosa, thicker epithelial linking, dilated crypt 
lumen, or a slightly raised appearance (Lopez-Ceron & Pellise, 2011).   
 
1.4 Clinical Utility of ACF 
 
Data on ACF prevalence range from 15% to 77% in healthy individuals and 
80% to 100% in patients with colorectal neoplasms (Lopez-Ceron & Pellise, 
2011).  ACF are thought to increase in size by a dynamic process known as 
crypt fission, although this mechanism is not well understood (Lopez-Ceron & 
Pellise, 2011).  
Colonic ACF may be predictive markers of future risk of CRC (Stevens 
et al., 2006).  ACF are the earliest identifiable morphological change in the 
pathway to CRC, according to Kinzler and Vogelstein (1996).  Both 
morphologically and genetically distinct, ACF may be precursors of adenoma 
and cancer. It has been shown, however, that ACF are a heterogeneous group 
of lesions, and while some may be important in CRC development, others are 
not (Stevens et al., 2006). 
 The number, size, and lumen morphology of ACF have been correlated 
with CRC risk (Lopez-Ceron & Pellise, 2011).  The total number and density 
(number/cm2) of ACF in the rectum tend to be representative of the amount of 
ACF present elsewhere in the colon (Lopez-Ceron & Pellise, 2011).  
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Accordingly, most endoscopic studies focus on rectal ACF (Lopez-Ceron & 
Pellise, 2011).  Crypt multiplicity, the number of crypts per focus, is correlated 
with ACF size (Lopez-Ceron & Pellise, 2011).  Studies have shown that as age 
increases, ACF size increases (Lopez-Ceron & Pellise, 2011).  Still, ACF size 
and risk of CRC are not clear (Lopez-Ceron & Pellise, 2011).  A recent study 
showed that small ACF were associated with distal adenomas (Lopez-Ceron & 
Pellise, 2011).  While some reports have shown an association between the 
shape of the lumen and dysplasia, other studies have found no correlation 
between the two (Lopez-Ceron & Pellise, 2011).        
The progression of CRC is a very lengthy process that can span up to 
two decades (Alrawi et al., 2006).  Intervention by polyp removal has now 
become a standard of clinical care (Alrawi et al., 2006).  Understanding the 
pathology of the colonic crypt can provide insight into the mechanisms of 
malignant transformation and could be key to identifying populations at 
increased risk of CRC and providing them with better preventative care 
measures (Alrawi et al., 2006).  
In a study by Sakai et al. (2011), significant stepwise increments in both 
prevalence and number of ACF were observed from normal to adenoma to 
CRC cases.  Mean number of ACF was also found to be significantly higher in 
the subject group with advanced adenoma than in the subject group with non-
advanced adenoma (Sakai et al., 2011).  These results indicate that ACF may 
  
  
 
 
 
8
serve as a reliable biomarker of human colorectal carcinogenesis (Sakai et al., 
2011).  
 ACF also harbor genetic and epigenetic alterations that can be detected 
in early neoplastic lesions and CRC (Lopez-Ceron & Pellise, 2011).  For 
example, mutations in the adenomatous polyposis coli (APC) gene have been 
strongly associated with dysplastic changes in ACF (Lopez-Ceron & Pellise, 
2011).  As a result, patients with familial adenomatous polyposis present with a 
high occurrence of dysplastic ACF (Lopez-Ceron & Pellise, 2011).  Conversely, 
a small proportion of dysplastic ACF show APC mutations in sporadic CRC 
while there is no evidence that hyperplastic ACF have this mutation (Lopez-
Ceron & Pellise, 2011).     
CRC carcinogenesis can also occur through microsatellite instability 
(MSI), a condition that results from defects in the normal DNA repair process 
due to the inactivation of certain genes, such as MLH1, MSH2, MSH6, or 
PMS2 (Lopez-Ceron & Pellise, 2011).  This inactivation can be either inherited 
(e.g., Lynch Syndrome) or acquired (e.g., MLH1 Promoter methylation) (Lopez-
Ceron & Pellise, 2011).  Fifteen percent of sporadic CRC is associated with 
MSI, and this frequency increases from ACF to adenoma to carcinoma (Lopez-
Ceron & Pellise, 2011).  Almost all patients with Lynch Syndrome present with 
ACF that show MSI (Lopez-Ceron & Pellise, 2011).  One study reported that a 
high concentration of MSI is found in adenomas of patients with Lynch 
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Syndrome, and 100% of ACF in these patients exhibited MSI (Lopez-Ceron & 
Pellise, 2011).   
An alternative pathway to the development of CRC, known as the 
serrated pathway, suggests the development of cancer without classic 
adenoma, but rather from serrated lesions related to hyperplastic polyps 
(Lopez-Ceron & Pellise, 2011).  Serrated lesions are thought to occur as a 
result of DNA modifications not related to modifying the basic structure of 
genes (Lopez-Ceron & Pellise, 2011).  The best-known epigenetic mechanism 
of CRC results from the inactivation of the hypermethylation of the promoter 
region of tumor suppressor genes (Lopez-Ceron & Pellise, 2011).      
ACF, while relatively common, in normal individuals, continue to be 
investigated as the earliest precursors of adenomas and cancers (Alrawi et al., 
2006).  While most ACF do not progress on to become cancerous, with some 
even regressing or disappearing, it is likely that certain factors induce them to 
become malignant (Alrawi et al., 2006).  The histomorphologic and/or genetic 
changes in ACF that lead to their potential role in neoplastic progression are 
still not well understood.  Studies on murine models have demonstrated that 
genetic cluster analyses are useful in identifying which murine ACF are high 
risk to go on to undergo malignant transformation (Alrawi et al., 2006).   
Alrawi et al. (2006) examined whether genomic instabilities exist in ACF 
from the normal, non-inflammatory setting.  Inter-(simple sequence repeat) 
PCR was used to quantify the genomic damage present in each ACF sample.  
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Even single base pair insertions or deletions can be identified through this 
technique (Alrawi et al., 2006).  Generally, however, detected genetic 
anomalies are found to be larger (Alrawi et al., 2006).  ACF from the same 
patient were observed to each have unique genomic fingerprints (Alrawi et al., 
2006).  Additionally, one-fourth of the thirty-two ACF examined revealed 
moderate instability after inter-PCR (Alrawi et al., 2006).  The results of this 
study indicate that ACF characterization could become a valuable clinical 
screening tool to identify those individuals that are more likely to develop 
colorectal carcinoma from instable ACF.                  
 
1.5 Risk Factors of ACF 
 
There are many factors thought to influence the natural history of ACF.  
Takayama et al. (1998) found that the prevalence and number of ACF 
increased abruptly between the ages of 40 and 50, and patients with cancer 
had a consistently higher prevalence and number of ACF, regardless of age.  
Patients on low dose aspirin have been shown to have lower prevalence of 
ACF, and lower prevalence of ACF have been reported in patients taking 
NSAIDs as well (Lopez-Ceron & Pellise, 2011).  These results have not been 
consistent, however.  Tobacco has been shown to be one agent that increases 
number of ACF in most studies (Lopez-Ceron & Pellise, 2011) and is an 
important risk factor for colorectal neoplasia (Anderson et al., 2010).  
  
  
 
 
 
11 
Alcohol is thought to induce ACF as well (Lopez-Ceron & Pellise, 2011), but 
the effects of different types of alcoholic beverages (e.g. beer, liquor, wine) are 
not well understood (Lopez-Ceron & Pellise, 2011).   
 
1.6 Conclusion 
 
There is growing evidence that statins may increase ACF number in humans, 
and that ACF may be precursor lesions of CRC, but much remains to be 
understood.  ACF are an efficient way to study this issue, but the role of statins 
in CRC development, with ACF as an intermediate, is still uncertain.  Indication 
bias due to adiposity could be at play here since statins could be prescribed to 
people who are more likely to be overweight and obese.  As such, these 
people may be at increased risk for high ACF count and subsequent CRC 
development.  This research project will incorporate adiposity measures and a 
wider range of circulating biomarkers in order to use ACF to provide insight into 
the role of statins in CRC.  It is thought that patients on statins will have a 
higher number of ACF than those not on statins, but this association will lessen 
once controlling for adiposity.  Using data from a pool of patients who received 
a standard colonoscopy at the Colon Cancer Prevention Program at the 
University of Connecticut Health Center, this investigation aims to: 
1. Determine the association between statin use and ACF 
number, controlling for key risk factors for CRC, and 
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2. Assess if the relationship between statin use and ACF count 
may be modified by controlling for different measures of 
adiposity (body mass index [BMI], waist circumference [WC], 
and waist-hip-ratio [WHR]).   
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2.0 METHODS 
 
2.1 Study Population 
 
We obtained data from 101 patients receiving standard colonoscopy at the 
Colon Cancer Prevention Program of the University of Connecticut Health 
Center from February 2010 to November 2011.  Patients attended the clinic for 
routine screening or surveillance following the detection of a pathological 
finding at a previous exam.  The goal of the clinic-based ACF study is to 
identify and describe the clinical importance of ACF and the epidemiologic risk 
factors for and molecular features of ACF and other early colonic neoplasia.  A 
total of 14 people were excluded because they were underweight (BMI < 18.5) 
or were missing adiposity measurements. 
 
2.2 Patient Data 
 
An Advanced Practice Nurse Practitioner (APRN) took measurement of height, 
weight, hip (i.e., widest torso circumference), and waist (i.e., narrowest torso 
circumference as defined in Gram et al. (2006).  A fasting blood sample (three 
heparinized vials at 10 ml) was drawn from the intravenous line at the 
colonoscopy exam and transported to the research laboratory.  Samples were 
separated into 0.5 ml aliquots and frozen at -80°C.  Patients were also 
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questioned about medication use, family history, personal history, and lifestyle-
behavior questions (e.g., tobacco and alcohol use).   
 
2.3 Colonoscopy Procedures and ACF Detection 
 
All patients in the study underwent routine colonoscopy for clinical purposes.  
Prior to the clinic visit, colon preparation was performed with a magnesium 
citrate based prep.  ACF detection, performed after the colonoscopy, lasted for 
up to 30 minutes.  High definition colonoscopes (Olympus PCF-H180AL and 
CFH-180AL) were utilized for examination purposes. Close focus properties 
allowed for clear, detailed observations.  
The distal 20 cm-section of colon, including the rectum, were washed.  
This was followed by water wash to remove mucous, after which examination 
was performed.  In order to visualize the colon, a fresh solution of indigo 
carmine 0.8% was prepared and applied for contrast staining using spray 
catheters.  The dye was allowed to absorb for two minutes before endoscopy 
was performed. A finding of an ACF is accepted if two or more crypts are 
darkly stained and have lumen diameters that are 1.5-2.0 times those of 
surrounding crypt lumens under close magnification.   
ACF were also required to be raised above the mucosal level. The 
requirements of being round, dilated, slit, or having a star-shaped lumen or 
thick crypt wall with compressed lumen were necessary to confirm 
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identification.  The colon was divided into four quadrants or the scope was 
withdrawn in a clockwise fashion as techniques to ensure that the ACF were 
not double-counted or missed.  Narrow-band imaging (NBI), which is a non-dye 
imaging technique that enhances mucosal and vascular detail, was used to 
detect ACF in some patients.       
The variability of the raters was addressed by including the requirement 
that the raters be trained in ACF determination and confer and reach an 
agreement on the determination of an ACF finding at the time of 
chromoendoscopy.  In the 20-cm distal region of the colon, ACF were counted 
and digital images were captured.  A maximum of 10 biopsy specimens of ACF 
were taken within the distal 20 cm using forceps (Precisor EXL, CR Bard). A GI 
pathologist (TVR), who was unbiased concerning the clinical findings, analyzed 
coded specimens of frozen section of ACF that had been stained with H&E 
(hematoxylin and eosin stain).  Histologic analysis was performed using light 
microscopy.  
 
2.4 Variables  
 
The number of ACF was categorized into two groups (<10, ≥10), termed low 
ACF and high ACF.  The median number of ACF was 9 and therefore, our 
outcome was having <10 or ≥10 ACF.   
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Statins were divided into <1 pill per week or ≥1 pill per week (regular 
use) in past 12 months.  Use of medications other than statins, including baby 
aspirin, aspirin, and other NSAIDs, were divided into never, <1 pill per week, 
or ≥ 1 pill per week.  In the logistic regression, these variables were split into 
two categories: <1 pill per week and ≥1 pill per week.  This was done to ensure 
no cell counts were too small.   
Biomarkers were analyzed as continuous variables.  BMI, WHR, WC, 
and age were analyzed as continuous variables as well as categorical.  The 
following groups defined categories of BMI for use in descriptive analysis: 
Normal (18.5–24.9), Overweight (25.0–29.9), Obese I (30.0–34.9), Obese II 
(35.0–39.9), and Obese III (≥40.0).  BMI was defined as weight divided by 
height (kg/m2).  As previously mentioned, underweight (BMI <18.5) participants 
were excluded from the study.   
WC and WHR were used as measures of central adiposity.  Cut-off 
levels for elevated WHR matched those defined by WHO criteria (Balkau et al., 
2002), namely >0.90 for males and >0.85 for females.  Elevated WC based on 
sex was defined as >40 in (102 cm) waist for males and >35 in (88 cm) for 
females (Swede et al., 2009).  
History of a first-degree relative with CRC was defined as having a 
parent, sibling, or child with a history of CRC.  Personal history of polyps 
was categorized as yes (a personal history of one or more polyp(s) in the past) 
or no (no personal history of polyps to date).    
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Smoking status was divided into three categories: never smokers, past 
smokers, and current smokers.  The following groups of categories defined 
alcohol consumption in analyses: red wine intake, white wine intake, beer 
intake, and liquor intake.  This alcohol consumption variable was further 
divided into the following classification scheme: never drinkers, individuals who 
consumed 0 to 3 drinks per month, and individuals who consumed ≥2 drinks 
per week.   
Finally, since there is a chance that people taking statins are on other 
anti-inflammatory drugs, we created a composite variable that was split into 
the following categories: no statin or aspirin use; statin use only; aspirin (baby 
or full-dose) use only; and statin and aspirin (baby or full-dose) use to assess 
the impact of individual vs. joint statin and aspirin use on ACF number.    
 
2.5 Enzyme-Linked Immunosorbent Assays (ELISAs) 
 
Blood specimens of 41 participants were available for ELISA analysis.  The 
following biomarkers from serum samples were measured: hsCRP (mg/L); IL-6 
(pg/mL); TNF-a (pg/mL); Insulin (ulU/mL); Glucose; Triglyceride; Cholesterol, 
Total; Cholesterol, HDL; IGF-1 (ng/mL); IGF-2 (ng/mL); IGFBP3 (ug/mL).   
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2.6 Statistical Analyses 
 
Descriptive analyses were performed for: age, sex, BMI, WHR, WC, 
medication (baby aspirin, full-dose aspirin, other NSAIDs), smoking, alcohol, 
personal history of polyps, and biomarkers as correlates of statin use and in 
relation to low versus high ACF number, using t-tests for continuous data and 
chi-square tests for proportions.   
Univariate, age-adjusted and various multivariate logistic regressions 
were conducted to calculate odds ratios (ORs) and 95% confidence intervals 
(95% CI) to identify the link between ACF number (i.e., outcome) and statin 
use (exposure.)  Statin use was assessed as regular statin use as well as the 
composite variable (i.e., joint use of aspirin and statins) in models.  To identify 
possible confounders of the relationship between statin use and ACF number, 
the univariate and age-adjusted logistic regressions were conducted for ACF 
number in relation to the following variables: age, sex, BMI, WHR, WC, 
medication use (baby aspirin, aspirin, other NSAIDs), smoking, alcohol 
consumption, personal polyp history, family history of CRC), and biomarkers 
  A base multivariate model was developed to include variables that 
were significant in univariate analyses (p <0.20) or were judged to be clinically 
important variables.  The base model included the following variables: statins, 
age, sex, medication use (baby aspirin, other NSAIDs), family history of CRC 
(first degree relative), personal polyp history, and smoking habits.  To 
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understand the effects of adiposity on ACF number, the base model was re-run 
to include, separately, BMI, WHR, and WC.  Also, since age is a key factor in 
most disease outcomes, including CRC development and progression, all 
multivariate logistic regressions were stratified by age (<50 years of age vs. 
≥50 years).   
Results for all tests were considered statistically significant if p<0.05 or 
results within the confidence intervals (95%) did not include 1.0.  SPSS version 
20.0 was used, and tests were two-sided in all the analyses.  
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3.0 RESULTS 
 
3.1 Participant Characteristics 
 
Demographics and adiposity measures of all eligible participants (n=86) are 
shown in Table 1.  In regards to statin use, 68.8% of the study population took 
<1 pill per week and 31.3% took 1 or more pills per week.  The mean age was 
56.79 years (SD 8.58).  Males made up 65% of the study sample while females 
accounted for 35%.  The majority of participants were White (90.7%), followed 
by Black (8.1%) and Asian (1.2%).  A slight majority (59.4%) of the participants 
had some college education, a 2-year degree, or a college degree.  About 21% 
of the study population had completed vocational or trade school, and 17.5% of 
the population had a high school education or less.   Nearly 1/5 (21%) of 
participants had a first degree relative (parent, sibling, or child) with a history of 
CRC, and about 18% of participants had a personal history of polyps.   
Regarding measures of excess body weight, the majority of participants 
were overweight or obese (72.1%).  Specifically, 27.9% of participants had a 
normal BMI (18.5-24.9), while 41.9% were overweight (BMI of 25.0-29.9) and 
30.2% were Obese (BMI of 30+).  The mean waist-hip-ratio (WHR) for males 
was 0.93 (SD 0.06), while the mean for females was 0.87 (SD 0.09).  When 
categorizing by WHO risk level, 28.6% of males had a normal WHR-risk 
(≤0.90), while 57.1% of males had an elevated WHR-risk.  In females, 33.3% 
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had a normal WHR-risk (≤0.85), while 56.7% had an elevated WHR-risk.  The 
mean waist circumference for males and females, respectively, was 38.05 (SD 
4.61) and 36.41 (SD 5.96).  With respect to waist circumference risk, 21.2% of 
males had an elevated risk (<40.0), compared to 48.1% of females (>35.0).   
 
3.2 Correlates of Regular Statin Use 
 
In order to identify potential confounders in the relationship between statin use 
and ACF number, we explored correlates of statin use and ACF number (see 
below.)    As seen in Table 2, participants who consumed at least 1 statin pill 
per week (i.e., regular use of statins), had a higher mean ACF number than 
participants who reported taking less than 1 pill per week (17.20 vs. 9.02, 
respectively, p=0.001).  We also categorized ACF number into low (<10) and 
high levels (≥10). Fewer participants with low ACF number reported taking 
statins on a regular basis compared to those with high ACF level (18.6% 
versus 47.2, respectively, p=0.006), As expected, the mean age for patients 
taking 1 or more statin pill per week was higher than the mean age for 
participants on less than 1 statin pill per week (62.40 (SD 7.69) vs. 54.51 (SD 
8.24), p<0.001).  In addition, patients aged 50 years and older were more likely 
to be on statin medication (1 or more pills per week) than those younger than 
50 years old (36.8% vs. 0, p=0.014).  There was no significant difference in 
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percentage of males or females on statin medication (33.3% vs. 26.9%, 
p=0.562).   
Regarding obesity measures, the mean BMI of participants taking 
statins on a regular basis was higher among those taking less than one pill per 
week (30.26 (SD 5.61) vs. 27.25 (SD 4.38), p=0.011).  Additionally, participants 
on a regular dosage of statins were more likely to be obese than those on <1 
pill per week (60.9% vs. 39.1%, p=0.001).  People taking statins regularly were 
also more likely to take baby aspirin on a weekly basis compared to those 
taking less than 1 statin pill per week (59.3% vs. 40.7%, respectively, p=0.001).        
 
3.3 Correlates of ACF Number 
 
To understand the relationship between the correlates of ACF number, t-tests 
for continuous data and chi-square tests for proportions were done with the 
following variables: medication use (statins, baby aspirin, aspirin, other 
NSAIDs), demographics (age, sex, race, education), personal polyp history, 
and family history of CRC.  Participants on a regular statin regimen were more 
likely to have a high ACF count than participants taking <1 statin pill per week 
(66.7% vs 37.1%, p=0.010).  As anticipated, the mean age for participants with 
a high ACF count (59.40) was higher than the mean age for participants with a 
low ACF count (54.17 years, p=0.002).  There were no significant differences 
between low and high ACF groups for participants based on sex, race, 
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education, personal polyp history, or a first degree relative with a history of 
CRC (Table 4).     
 Adiposity was explored as a correlate of ACF number (high vs. low) by 
analyzing BMI, WHR, WHR-risk, and WC.  As predicted, the mean BMI for the 
low ACF group was less than that of the high ACF group (27.21 vs. 28.99, 
respectively, p=0.152).  There were no significant differences between the low 
and high ACF groups in waist-hip-ratio, waist-hip ratio risk level, or waist 
circumference.  There was a marked difference, however, when smoking was 
analyzed as a correlate of ACF (Table 6).  Never and past smokers were more 
likely to be in the low ACF group than current smokers (58.9% vs. 60.0% vs. 
18.2%, p=0.037).  Eighty-one percent of current smokers fell into the high ACF 
group vs. 40.0% and 41.1% of past and never smokers, respectively.  There 
were no significant differences between beer, red wine, and white wine 
consumption and ACF count.  Almost 82% of participants that consumed 2 or 
more drinks of liquor per week, however, had high ACF, compared to 42.9 and 
40.4% of participants who had 0-3 drinks per month or did not drink on a 
regular basis (p=0.039).  When serum biomarkers were analyzed as correlates 
of ACF, there were no significant differences between the measured 
biomarkers and ACF count, with the exception of insulin levels (Table 7).  The 
mean level of insulin (ulU/mL) in the high ACF group compared to the low ACF 
group was 5.84 vs. 3.44 (p=0.035).   
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3.4 Univariate and Age-Adjusted Logistic Regression Assessing the 
Relationship between Regular Statin Use and ACF Number 
 
We calculated univariate and age-adjusted Odds Ratios (ORs) and 95% 
Confidence Intervals (95% CIs) in order to identify variables that might have an 
association between statin use and ACF number (Table 8). Compared to 
people taking <1 statin pill per week, people with regular statin use were 3.91 
times more likely to have a high ACF count (95%CI=1.43-10.74, p=0.008).  
Age, current smoking, and frequent liquor intake were also shown to increase 
the risk for having a high ACF count.  Participants age 50 years and older were 
3 times more likely to have high ACF than those younger than age 50 
(95%CI=0.77-12.32), and current smokers had a 4.90 times greater odds of 
having high ACF compared to never smokers (95%CI=0.92-26.11).  
Additionally, the age-adjusted OR for high ACF was 6.21 (95%CI= 1.22-31.78) 
when comparing users of high level of liquor (≥3 drinks per week) with never 
users of liquor.  No significant differences in the logistic regression were noted 
for the following variables: sex, BMI, WHR, WC, baby aspirin, aspirin, other 
NSAIDs, red white, white wine, beer, personal history of polyps, and family 
history of CRC.   
Age-adjusted ORs for the logistic regression are shown in Table 8.  After 
adjusting for age, the OR for high ACF of taking ≥1 statin pill per week vs. 
taking <1 pill per week decreased to 2.67 (95%CI=0.89-7.97) and was no long 
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statistically significant.  The OR for high ACF and being a current smoker 
compared to being a non-smoker, on the other hand, increased to 7.17 
(95%CI=1.22-42.17) and became statically significant (p=0.029).  The OR for 
high ACF of having a high intake of liquor vs. no liquor intake increased to 7.13 
(95%CI=1.33-38.35) and remained statistically significant (p=0.022) after age 
adjustment.   
Univariate and age-adjusted ORs and 95% CIs were additionally 
measured in order to identify serum inflammatory or adiposity-related 
biomarkers that might have an association between statin use and ACF 
number (Table 9).  Insulin was the only biomarker that showed statistical 
significance in the crude and age adjusted logistic regressions (Crude OR: 1.31 
(95%CI=1.01-1.70), p=0.045; Age-adjusted OR: 1.33 (95%CI=1.01-1.75) 
p=0.039).  The following serum biomarkers were not significantly associated 
with ACF number in both the crude- and age-adjusted logistic regressions: 
IGF-2, hsCRP, IGFBP3, IGF1, IL-6, TNF-a, glucose, total cholesterol, and HDL 
cholesterol.         
 
3.5 Base Multivariate Logistic Regression 
 
Variables that were related to ACF in the Univariate model or were judged to 
have clinical value were placed in the multivariate model.  The results for the 
multivariate regression base model can be found in Table 10.  The OR for high 
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ACF in relation to regular statin use compared to no statin use was 1.47 
(95%CI=0.28-7.74).  Unlike the univariate estimate, this was no longer 
statistically significant (p=0.652).  The OR for high ACF of age was 1.10 
(95%CI=0.99-1.22; p=0.065), and the OR for high ACF of being a current 
smoker in comparison to having never smoked was 4.80 (95%CI=0.61-37.68; 
p=0.136) in the multivariate logistic regression.  There was no statistical 
significance of any variables after stratifying the base model by age (≥50 years 
vs. <50 years old) (Table 14).        
 
3.6 Adding Obesity Measures into the Base Multivariate Model 
 
In order to understand if adiposity influences the association between ACF 
number and statin use, BMI, WHR, and WC were added into the base model 
individually.  The results for the multivariate logistic regression BMI model can 
be found in Table 11.  The OR for high ACF of regular statin use compared to 
no statin use was 1.24 (95%CI=0.21-7.47; p=0.017).  The OR for high ACF of 
age was 1.11 (95%CI=1.00-1.23; p=0.063).  Current smokers had more than 5 
times greater odds of having high ACF than non-smokers (OR: 5.43; 
95%CI=0.64-46.32; p-0.122).  After stratifying for age (≥50 years vs. <50 years 
old), there was no longer statistical significance of any of the variables 
measured in the BMI model.    
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The results for the multivariate logistic regression WHR model can be 
found in Table 12.  The OR for high ACF and regular statin use compared to no 
regular statin intake was 0.68 and no longer statistically significant 
(95%CI=0.10-5.40; p=0.702).  Age, however, was significantly associated with 
high ACF number in the WHR model.  The OR for age was 1.15 (95%CI=1.01-
1.32; p=0.035), and the OR for high ACF of being a current smoker compared 
to non-smokers was 7.62 (95%CI=0.79-73.37; p=0.079).  After stratifying for 
age (≥50 years vs. <50 years old) (Table 16), none of the variables showed 
statistical significance any longer. 
The results for the multivariate logistic regression WC model can be 
found in Table 13.  The OR for high ACF of regular statin use vs. no statin use 
was 1.20 (95%CI=0.20-1.20; p=0.842).  The OR for high ACF of age was 1.12 
(95%CI=0.99-1.26; p=0.62) and the OR for high ACF of being a current smoker 
vs. non-smoker was 2.58 (95%CI=0.54-38.54; p=0.162).  After age 
stratification (≥50 years vs. <50 years old) (Table 17), there was still no 
statistical significance for statin use.  The OR for high ACF of age was 1.19 
(95%CI=1.00-1.41; p=0.054), and the OR for high ACF of currently smoking vs. 
non-smoking was 3.30 (95%CI=0.25-43.07; p=0.363).  No variables showed 
statistical significant in either of the WC models.   
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3.7 Composite Variable of Joint Aspirin and Statin Use 
 
In assessing the impact of joint statin and aspirin use, compared to individual 
use of these medications, we found that the crude OR for high ACF of taking 
statins compared to no statins or aspirin was 15 (p=0.019), compared to 1.83 
(p=0.293) for aspirin only, and 4.29 (0.022) for statins and aspirin.  After 
adjusting for age, they reduced to 11.03 (p=0.042), 1.35 (p=0.622), and 2.26 
(p=0.265), respectively.  After controlling for age, sex, NSAID use, family 
history of CRC, personal polyp history, and smoking in the multivariate model, 
the OR for high ACF of taking statins compared to no statin or aspirin use was 
2.06 (p=0.620), compared to 0.45 (p=0.369) for aspirins only, and 0.45 
(p=0.535) for statins and aspirins.  Results for the composite statin and aspirin 
variable can be found in Table 17.     
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4.0 DISCUSSION 
 
4.1 Key Findings 
 
About 30% of our study population took statins on a regular basis (i.e., ≥1 pill 
per week for the past 12 months).  Participants on a regular statin regimen had 
almost twice the number of mean ACF than those not taking statins regularly, 
which was statistically significant.  Additionally, two-thirds of participants with 
regular statin use were categorized as having high ACF in comparison to a little 
over a third of participants who reported little or no statin use.  Univariate 
logistic regression analyses showed that patients regularly taking statins had 
close to four times the likelihood of high levels of ACF than those not taking 
statins regularly.  After adjustment for age, the OR reduced to just below 3.0 
but did not remain statistically significant.  When potential confounders were 
placed in the multivariate base model, this effect lessened, more so, with statin 
users having an approximately 1.5 times greater odds of having high ACF than 
non-statin users.  OR estimates from neither the base model nor each of the 
three models with the adiposity measures were statically significant.     
When examining joint use of statins and aspirin, univariate logistic 
regression suggested that participants who consumed statins (only) on a 
regular basis were 15 times more likely to have a high ACF count compared to 
the reference group of participants who consumed neither aspirin nor statins 
  
  
 
 
 
30 
regularly.  In the age-adjusted and multivariate models, however, this effect 
was attenuated substantially and became non-significant.  Of note, though not 
statistically significant, the odds of having a high ACF count among statin-only 
users was 2 times greater than odds among users of neither statin nor aspirin.  
 
4.2 Consistency with Prior Studies on Statins and Colorectal Neoplasia 
 
Our univariate logistic regression analyses of a positive association with ACF 
number are inconsistent with animal studies, which have suggested uniformly 
that statins lower the risk of colonic neoplasia (NCI, 2005).  As predicted, 
virtually all of our multivariate analyses reduced the OR estimates to null.  One 
such animal study, Narisawa et al. (1994), examined the effects of pravastatin 
and simvastatin on mice that received injections of 1,2-dimethylhydrazine 
(DMH) to induce colon cancer development and found that the incidence of 
colon tumors examined at weeks 25 or 30 was reduced by 67% in the 
pravastatin group and by 30% in the simvastatin group (Narisawa et al., 1994).  
While these results did not reach statistical significance, there was a 
considerable reduction in the number of tumors per mouse in both groups 
(Narisawa et al., 1994).   
Evidence from human studies has been quite mixed.  We believe, in 
part, this is due to all reports on statins and colonic neoplasia in humans 
having been derived from secondary analyses, with the recent exception of a 
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multicenter, phase II trial of statins for CRC chemoprevention by Limburg et al. 
(2011).  Using ACF as the intermediate endpoint, Limburg (2011) reported a 
lack of convincing evidence that six months of statin use (atorvastatin or 
sulindac) reduced ACF number.   
Singh et al. (2009) did not find any statistically significant reductions in 
CRC risk with regular use of statins, irrespective of duration and dose.  Oddly, 
however, they did find a slightly increased risk with low dose statin intake 
among regular users compared to nonusers of statins.  Low doses of statins 
have been shown to have a stimulatory effect on CRC cell lines (Kodach et al., 
2007).  Poynter et al. (2005) reported a 47% reduction in CRC risk among 
individuals using statins for 5 or more years.  Hence, ascertaining dose may be 
in critical in human studies.  
A recent study by Bertagnolli et al. (2010) suggests that for patients at 
high risk of CRC (e.g., patients with multiple adenomas or patients who have 
had a single adenoma ≥6 mm in diameter removed), statins do not protect 
against colorectal neoplasms and may even increase the risk of developing 
adenomas.  These findings are consistent with early clinical trials that suggest 
that statin use might increase cancer risk (Alsheikh & Karas, 2009; Oliver, 
1991; Rossebo et al., 2008; Shepherd et al., 2002).  In the Bertagnolli (2010) 
study, participants who used statins for more than 3 years in the placebo group 
of the Adenoma Prevention with Celecoxib (APC) trial showed a 40% increase 
in adenoma detection over 5 years of surveillance. 
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On the other hand, Siddiqui et al. (2009) found that long-term statin use 
was associated with a 29% reduction in the incidence of new and advanced 
adenomatous colon polyps (APs) in patients that had previously had APs 
removed colonoscopically.  This association remained, even after controlling 
for other known risk factors (Siddiqui et al., 2009).  These data suggest that 
statins may decrease the development of CRC by reducing the development of 
new APs (Siddiqui et al., 2009), yet it is unknown what the incidence of ACF 
was.   
Regarding evidence of indication bias related to adiposity, our study is 
inconclusive in that OR estimates were reduced in the base model prior to the 
introduction of adiposity measures into the model.  While our adiposity results 
are not statistically significant, our data do show similar tends to Swede et al. 
(2009) in that higher adiposity levels seem to be associated with high ACF 
count.    In terms of the association between adiposity and ACF number, 
Swede et al. (2009) found that high ACF count was significantly associated 
with higher BMI, WHR, and WC compared to people with low ACF.  However, 
high ACF was defined as ≥5 whereas the cut point for the current study count 
was 10 ACF.   
Our descriptive findings on the relationship between elevated BMI, 
WHR, and WC and increased ACF number are also consistent with a report by 
Takahashi et al. (2007), who found that a high level of visceral fat was 
associated with elevated ACF number.  While our findings do not show a 
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statistically significant relationship between high ACF number and obesity, high 
WHR, and high WC, we did observe similar general trends.  Individuals who 
were obese (BMI ≥30) were more likely to have a higher ACF count than 
individuals with normal BMI (18.5-24.9).  Additionally, both males and females 
with high ACF had slightly higher mean WHR values.  Our findings are 
consistent with findings reported by Swede et al. (2009), in terms of this 
relationship being stronger in females than males.  Furthermore, over half of 
participants with elevated WHR-risk were more likely to fall into the high ACF 
group.  
In relation to WC, both males and females in the high ACF group tended 
to have a higher mean WC.  Females in the high ACF group had a slightly 
higher mean WC than that of those in the low ACF group.  In males, this 
association was slightly stronger.  While our findings reported WC to be 
associated with high ACF more strongly in males, Swede et al. (2009) found 
the opposite.  Females with a higher WC were more strongly associated with 
high ACF than males (p=0.06 for females; p=0.17 for males) (Swede et al., 
2009).   
 In reference to other lifestyle behaviors that affect CRC risk, smoking 
use and alcohol consumption are thought to induce ACF (Lopez-Ceron & 
Pellise, 2011).  However, the effects of different types of alcoholic beverages 
(e.g. beer, liquor, wine) are not well understood (Lopez-Ceron & Pellise, 2011).  
In our study, over 80% of current smokers had high ACF.  Current smokers 
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had an almost 5 times greater odds of having high ACF as opposed to non-
smokers in the multivariate model.  Additionally, frequent liquor consumption 
was significantly associated with high ACF count.  
 In regards to family history of CRC, Stevens et al. (2007) reported a 
significantly higher mean ACF number in patients with a positive family history 
of CRC in a first degree relative or a personal history of CRC (p<0.01 and 
p<0.05, respectively).  Surprisingly, having a first-degree relative with CRC did 
not make participants more likely to have a higher ACF number in our study, 
nor did we see a link with polyps.   
In terms of conventional anti-inflammatory medications, many 
observational studies have noted a lower CRC risk in association with regular 
intake of aspirin or NSAIDs (Simon, 2012).  This was not quite as clear in our 
study, but, as described below, our findings about ACF were consistent with 
other observational studies in that there was a lower percentage of participants 
with high ACF in regular users of these anti-inflammatory medications in 
comparison to non-regular users.     
Regarding baby aspirin use, we found that about two-thirds of 
participants taking low levels (i.e., <1 pill per week for past 12 months) had 
high ACF, compared to about half of regular aspirin users.  Among regular 
aspirin users, 30% had a high ACF count compared to almost 62% of 
participants who took <1 pill per week.   
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While many studies have found that the sustained use of aspirin and 
other NSAIDs may decrease the incidence of APs and CRC and may decrease 
the mortality rate from CRC (Siddiqui et al., 2009), the gastrointestinal and 
other serious toxicities of NSAIDs limit their utility for the chemoprevention of 
CRC, especially in the older populations in which CRC is most prevalent 
(Siddiqui et al., 2009).   
Age was significantly associated with high ACF count in our study.  
Participants on regular statins had a mean age 5 years greater than those 
taking <1 pill per week.  People older than 50 that took statins did have slightly 
increased odds of high ACF in comparison to those younger than 50 in the 
multivariate model.  Swede et al. (2009), however, did not find age to be 
significantly associated with high ACF.  The mean age of individuals in the high 
ACF group (≥5 ACF) was slightly higher than the low ACF group (<5 ACF).  
 
4.3 Strengths and Limitations  
 
A major advantage of our study was the creation of a composite variable in 
which we assessed joint statin and aspirin use.  Since, it is likely that patients 
on statins could be on other anti-inflammatory drugs (i.e., aspirin) for the long-
term, we were able to examine the effects of statin use alone.  Our results 
should be approached with caution, however, as we had a very small sample 
size in one of our study groups (e.g., n=7 for statins only).  Understanding the 
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impact of a combination of different medications, and taking into account 
confounding between medications, should be a goal of future studies.   Another 
strength of our study was that several inflammatory, adiposity, and lipid-
associated biomarkers were assessed in relation to ACF number.  Perhaps 
because of the small number of patients with these values (n=41), results were 
not conclusive.  Also, the link between alcohol use and colonic neoplasia is not 
well understood, but we were able to broadly examine it in this study by 
comparing beer, liquor and wine intake to ACF count.   
There are several limitations of this study.  First, dietary intake and 
physical activity were not taken into account in our multivariate model.  Both of 
these have shown to have an impact on ACF number and CRC risk and could 
have affected our results.  Due to several methodical issues in measuring and 
evaluating physical activity, we chose not to include it in our study.  A second 
limitation of this study is that biomarker levels were measured as one point in 
time.  It is conceivable that serum levels of some biomarkers (cholesterol, 
insulin, glucose, etc.) can vary from baseline to reassessment.  ACF number 
also shows dynamic variability (Schoen et al., 2008), but was measured at only 
a single point in time  
Another key limitation of this study is the small size of the study 
population.  The number of people taking ≥1 statin pill per week (i.e., regular 
statin use) was very low (n=25, 31.3%).  This could potentially have resulted in 
unreliable estimates.  Finally, type of statin use may influence tissue response 
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(Bertagnolli et al., 2010).  While hydrophilic statins (e.g., fluvastin, rosuvastatin, 
pravastatin) are hepatoselective, lipophilic statins (e.g., lovastatin, simvastatin, 
atorvastin) tend to achieve higher drug levels in nonhepatic tissues and are 
thought to alter colorectal mucosa more (Bertagnolli et al., 2010).  In an 
analysis using the Women’s Health Initiative, Simon et al. (2012) found no 
overall protective effect of statins for CRC.  A significant reduction was 
observed in CRC risk, however, for lovastatin users and a modest, but 
insignificant reduction for overall statin use of ≥3 years.  
 
4.4 Conclusions 
 
While statin use was associated with a significantly higher ACF count in our 
study population in univariate analyses, this effect did not remain after 
controlling for confounders.  After adding measures of adiposity (BMI, WHR, 
WC) to the multivariate base model, only increased age and current smoking 
status remained associated with ACF number.  Since CRC can take up to 20 
years to develop, insufficient drug exposure and follow-up could be the culprit 
to a lack of consensus on the topic (Bertagnolli et al., 2010).      
Future studies should focus more on length of time of statin use, 
perhaps by breaking it down into more discrete categories, as well as type of 
statin and dosage.  Additionally, regular use of statins needs to be 
standardized.  Most studies define regular statin use differently, making it 
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difficult to compare results.  Finally, there is a need for studies to address 
indication bias, especially as adiposity continues to garner interest as a 
modifiable risk factor in CRC.  It could be that statins are prescribed more often 
to people who are at high risk of acquiring CRC.  Thus, it could appear that 
statins are causing high ACF number, when they are in fact being prescribed 
more often to those at high risk for CRC.  Further exploration of these topics 
may provide a greater understanding of the inter-relationships of statins, 
adiposity, and CRC, leading to effective preventive interventions that will 
improve the public health. 
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Table 1: Description of Study Population (n=86) 
 
 
Statin Use in Past 12 months <1 pill per week 55 (68.8%) 
 ≥1 pill per week 25 (31.3%) 
Age (mean, SD) 
 56.79 (8.58) 
Age <50 yrs 12 (14%) 
 ≥50 yrs 74 (86%) 
Sex Male 56 (65.1%) 
 Female 30 (34.9%) 
Race White 78 (90.7%) 
 Black 7 (8.1%) 
 Asian 1 (1.2%) 
Education Less than High School 5 (5.9%) 
 High School or GED  10(11.6%) 
 Vocational or Trade School 18 (20.9%) 
 Some College 20 (23.3%) 
 2-year Degree 17 (19.8%) 
 At Least College Degree 14 (16.3%) 
1st Degree Relative with CRC 
 Yes 18 (20.9%) 
 No 61 (70.9%) 
Personal History of Polyps Yes 14 (17.7%) 
 No 65 (82.3%) 
BMI Normal (18.5-24.9) 24 (27.9%) 
 Overweight (25.0-29.9) 36 (41.9%) 
 Obese (30+) 26 (30.2%) 
Waist-hip-ratio (mean, SD) Male 0.93 (0.06) 
 Female 0.87 (0.09) 
Waist-Hip-Ratio Risk Male Normal (≤0.90) 16 (28.6%) 
 High (>0.90) 32 (57.1%) 
 Female Normal (≤0.85) 10 (33.3%) 
 High (>0.85) 17 (56.7%) 
Waist Circumference (mean, SD) Male 38.05 (4.61) 
 Female 36.41 (5.96) 
Waist Circumference Risk Male Normal (≤40.0) 41 (78.8%) 
 High (>40.0) 11 (21.2%) 
 Female Normal (≤35.0) 14 (51.9%) 
 High (>35.0) 13 (48.1%) 
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Table 2: Correlates of Regular Statin Use (n=86) 
 
 
Weekly Statin Use 
Past 12 Months 
<1 pill ≥1 pill p-value1 
ACF number 
 9.02 17.20 0.001 
ACF Number Low (<10) 35 (81.4%) 8 (18.6%) 0.006 
 High (≥10) 19 (52.8%) 17 (47.2%)  
Age (mean, SD) 
 54.51 (8.24) 62.40 (7.69) <0.001 
Age <50 years 12 (100%) 0  
 ≥ 50 years 43 (63.2%) 25 (36.8%) 0.014 
Sex Male 36 (66.7%) 18 (33.3%) 0.562 
 Female 19 (73.1%) 7 (26.9%)  
1st Degree Relative with CRC Yes 12 (66.7%) 6 (33.3%) 0.969 
 No 38 (69.1%) 17 (30.9%)  
Personal History of Polyps Yes 13 (65.0%) 7 (35.0%) 0.418 
 No 30 (75.0%) 10 (25.0%)  
Body Mass Index (mean, SD) 
 27.25 (4.38) 30.26 (5.61) 0.011 
Body Mass Index Normal [18.5-24.9] 18 (75.0%) 6 (25.0%) 0.001 
 Overweight [25.0-29.9] 28 (84.8%) 5 (15.2%)  
 Obese [30+] 9 (39.1%) 14 (60.9%)  
Sex-specific Waist-Hip-Ratio Risk Normal 21 (80.8%) 5 (19.2%) 0.091 
Elevated 27 (61.4%) 17 (38.6%)  
Waist Circumference (mean, SD) 
 36.44 (4.87) 39.28 (5.10) 0.022 
Baby Aspirin Never 41 (82.0%) 9 (18.0%) 0.001 
 <1 pill/week 2 (100%) 0  
 ≥1 pill/week 11 (40.7%) 16 (59.3%)  
Regular Aspirin Never 39 (68.4%) 18 (31.6%) 0.683 
 <1 pill/week 10 (76.9%) 3 (23.1%)  
 ≥1 pill/week 6 (60.0%) 4 (40.0%)  
Other NSAIDS Never 24 (77.4%) 7 (22.6%) 0.080 
 <1 pill/week 20 (74.1%) 7 (25.9%)  
 ≥1 pill/week 11 (50.0%) 11 (50.0%)  
Smoking Never 34 (70.8%) 14 (29.2%) 0.865 
 Past 16 (66.7%) 8 (33.3%)  
 Current 5 (62.5%) 3 (37.5%)  
Alcohol Red Wine Never 32 (71.1%) 13 (28.9%) 0.813 
 0-3 drinks /month 12 (63.2%) 7 (36.8%)  
 ≥2 drinks per week 10 (66.7%) 5 (33.3%)  
White Wine Never 39 (67.2%) 19 (32.8%) 0.939 
 0-3 drinks /month 5 (71.4%) 2 (28.6%)  
 ≥2 drinks per week 10 (71.4%) 4 (28.6%)  
Beer Never 28 (62.2%) 17 (37.8%) 0.211 
 0-3 drinks /month 13 (68.4%) 6 (31.6%)  
 ≥2 drinks per week 13 (86.7%) 2 (13.3%)  
Liquor Never 36(72.0%) 14 (28.0%) 0.522 
 0-3 drinks /month 12 (66.7%) 6 (33.3%)  
 ≥2 drinks per week 6 (54.5%) 5 (45.5%)  
1 T-tests for independent samples for continuous data and chi-square test for proportions 
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Table 3: Correlates of Statin Use: Biomarkers Related to Inflammation, Insulin Resistance, and Lipid Levels 
(n=41) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weekly Statin Use 
 
Past 12 Months 
 
Never ≥1 pill p-value1 
hsCRP, mg/L 4.22 4.94 0.734 
IL-6, pg/mL 62.86 31.10 0.282 
TNF-a, pg/mL 5.78 4.17 0.234 
Insulin, ulU/mL 4.41 4.38 0.980 
Glucose 88.17 89.29 0.913 
Triglyceride 105.83 88.07 0.245 
Cholesterol, Total 185.72 189.86 0.705 
Cholesterol, HDL 49.94 58.43 0.166 
IGF-1, ng/mL 122.80 110.64 0.235 
IGF-2, ng/mL 758.16 685.07 0.064 
IGFBP3, ug/mL 5.07 4.44 0.045 
  
  
 
 
 
49 
Table 4: Correlates of ACF Number: Demographics, Medication Use, Personal Polyp History, and 1st Degree 
relative with Colorectal Cancer (n=86) 
 
 
 
ACF Number 
Low (<10) High (≥10) p-value1 
Statin Use  
(Past 12 months) 
<1 pill/week 39 (62.9%) 23 (37.1%) 0.010 
≥1 pill/week 9 (33.3%) 18 (66.7%)  
Baby Aspirin None 30 (60.0%) 20 (40%) 0.390 
 <1 pill/week 1 (33.3%) 2 (66.7%)  
 ≥1 pill/week 12 (46.2%) 14 (53.8%)  
Aspirin None 31 (54.4%) 26 (45.6%) 0.381 
 <1 pill/week 5 (38.5%) (8) 61.5%  
 ≥1 pill/week 7 (70.0%) 3 (30.0%)  
Other NSAIDs None 19 (61.3%) 12 (38.7%) 0.556 
 <1 pill/week 13 (48.1%) 51.9% (14)  
 ≥1 pill/week 11 (50%) 11 (50%)  
Age (years) Mean 54.17 59.40 0.002 
 Range 51.82-56.52 57.03-61.78  
Sex Male  33 (52%) 29 (46.8%) 0.685 
 Female 19 (57.6%) 14 (42.4%)  
Race White 42 (54.5%) 35 (45.5%) 0.268 
 Black 2 (28.6%) 5 (71.4%)  
 Asian 1 (100%) 0  
Education Less than High School 1 (20%) 4 (80%) 0.520 
 High School or GED 6 (60%) 4 (40%)  
 Vocational/Trade School 12 (66.7%) 6 (33.3%)  
 Some College 9 (45%) 11 (55%)  
 2 Year Degree 8 (50%) 8 (50%)  
 4 or 5 Year Degree 9 (64.3%) 5 (35.7%)  
Personal Polyp History Yes 9 (42.9%) 12 (57.1%) 0.165 
 No 24 (61.5%) 15 (38.5%)  
1st Degree Relative with 
CRC  
Yes 11 (61.1%) 7 (38.9%) 0.668 
No 31 (51.7%) 29 (48.8%)  
1T-tests for independent samples for continuous data and chi-square test for proportions 
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Table 5: Correlates of ACF Number: Adiposity 
 
 
 
ACF Number 
Low (<10) High (≥10) p-value1 
Body Mass Index (kg/m2) 
 27.21 (SD)2 28.99 (SD) 0.152 
Body Mass Index Normal [18.5-24.9] 14 (58.3%) 10 (41.7%) 0.634 
 Overweight [25.0-29.9] 20 (57.1%) 15 (42.9%)  
 Obese [≥30] 11 (42.3%) 15 (57.5%)  
Waist-Hip-Ratio Male 0.92 (0.07) 0.93 (0.06) 0.788 
 Female 0.86 (0.07) 0.89 (0.11) 0.405 
Waist-Hip-Ratio Risk Normal 18 (62.1%) 11 (37.9%) 0.196 
 Elevated 24 (47.1%) 27 (52.9%)  
Waist Circumference Male 37.14 (5.23) 38.89 (3.87) 0.174 
 Female 36.22 (5.85) 36.59 (6.59) 0.883 
1 T-tests for independent samples for continuous data and chi-square test for proportions 
 
2 Mean (SD) 
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Table 6: Correlates of ACF Number: Smoking and Alcohol 
 
 
 
ACF Number 
Low (<10) High (≥10) p-value1 
Smoking Never 33 (58.9%) 23 (41.1%) 0.037 
 Past 15 (60.0%) 10 (40.0%)  
 Current 2 (18.2%) 9 (81.8%)  
Alcohol Beer Never 27 (50.9%) 26 (49.1%) 0.694 
  0-3 drinks/month 13 (61.9%) 8 (38.1%)  
  ≥2 drinks/week 8 (53.3%) 7 (46.7%)  
 Liquor Never 34 (59.6%) 23 (40.4%) 0.039 
    0-3 drinks/month 12 (57.1%) 9 (42.9%)  
  ≥2 drinks/week 2 (18.2%) 9 (81.8%)  
 Red Wine Never 28 (53.8%) 24 (46.2%) 0.667 
  0-3 drinks/month 10 (47.6%) 11 (52.4%)  
  ≥2 drinks/week 10 (62.5%) 6 (37.5%)  
 White Wine  Never 37 (56.1%) 29 (43.9%) 0.783 
                0-3 drinks/month 4 (50.0%) 4 (50.0%)  
                ≥2 drinks/week 7 (46.7%) 8 (53.3%)  
1 T-tests for independent samples for continuous data and chi-square test for proportions 
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Table 7: Correlates of ACF Number: Biomarkers of Inflammation, Insulin Resistance, and Lipid Levels (n=41) 
 
 
 
ACF Number 
Low (<10) High (≥10) p-value2 
hsCRP (mg/L) 4.09 (4.08)1 5.39 (7.23)1  0.507 
IL-6 (pg/mL) 87.79 (215.97) 57.90 (99.82) 0.614 
TNF-a (pg/mL) 5.45 (3.66) 4.51 (3.24) 0.473 
Insulin (ulU/mL) 3.44 (2.78) 5.84 (3.16) 0.035 
Glucose  86.72 (27.93) 90.47 (28.20) 0.705 
Triglyceride 97.33 (48.20) 98.47 (33.87) 0.939 
Cholesterol, Total 185.78 (28.02) 186.33 (34.72) 0.960 
Cholesterol, HDL 52.00 (12.09) 54.27 (22.16) 0.712 
IGF-1 (ng/mL) 116.54 (21.38) 126.07 (37.05) 0.348 
IGF-2 (ng/mL) 710.96 (110.43) 772.05 (116.38) 0.121 
IGFBP3 (ug/mL) 4.80 (0.95) 5.05 (1.04) 0.457 
1 Standard deviation for continuous variables 
2 T-tests for independent samples for continuous data  
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Table 8: Univariate and Age-Adjusted Odds Ratios and 95% Confidence Intervals for ACF Number in relation to 
Key CRC Risk Factors 
 
 
Crude Age-Adjusted 
 
OR (95% CI) p-value OR (95% CI) p-value 
Statins <1 pill per week 1.00  1.00  
 ≥ 1 pill per week 3.91 (1.43-10.74) 0.008 2.67 (0.89-7.97) 0.079 
Age 1.08 (1.02-1.14) 0.009 - - 
Age  < 50 years 1.00  1.00  
 ≥ 50 years 3.08 (0.77-12.32) 0.111 1.10 (0.21-1.15) 0.910 
Sex 0.71 (0.29-1.75) 0.451 0.65 (0.25-1.71) 0.385 
BMI 1.06 (0.98-1.16) 0.159 1.06 (0.97-1.14) 0.207 
BMI  Normal 1.00  1.00  
 Overweight 0.95 (0.33-2.73) 0.928 0.95 (0.31-2.91) 0.927 
 Obese 1.82 (0.65-5.08) 0.254 1.68 (0.58-4.81) 0.337 
Sex-specific Waist-
Hip-Ratio Risk 
Normal 1.00  1.00  
Elevated 1.89 (0.72-5.00) 0.199 1.50 (0.53-4.21) 0.443 
Waist Circumference 1.06 (0.96-1.15) 0.243 1.04 (0.95-1.14) 0.431 
Baby Aspirin 1.64 (0.64-4.23) 0.303 0.89 (0.30-2.66) 0.833 
Aspirin  0.45 (0.11-1.90) 0.279 0.44 (0.10-1.91) 0.272 
Other NSAIDs <1 pill per week 1.00  1.00  
 ≥ 1 pill per week 1.23 (0.46-3.29) 0.679 1.15 (0.42-3.19) 0.784 
Smoking  Never 1.00  1.00  
 Past 1.00 (0.37-2.70) 1.000 1.02 (0.35-2.97) 0.969 
 Current 4.90 (0.92-26.11) 0.063 7.17 (1.22-42.17) 0.029 
Red Wine  None 1.00  1.00  
 0-3 drinks per month 1.27 (0.43-3.72) 0.663 1.23 (0.40-3.85) 0.719 
 ≥ 3 drinks per week 0.76 (0.23-2.50) 0.654 0.69 (0.20-1.14) 0.554 
White Wine None 1.00  1.00  
 0-3 drinks per month 1.76 (0.36-8.58) 0.484 1.67 (0.32-8.64) 0.540 
 ≥ 3 drinks/week 1.76 (0.54-5.72) 0.347 1.67 (0.49-5.76) 0.414 
Beer None 1.00  1.00  
 0-3 drinks per month 0.76 (0.26-2.24) 0.620 0.93 (0.29-2.92) 0.897 
 ≥ 3 drinks per week 0.92 (0.28-2.95) 0.881 1.32 (0.38-4.61) 0.663 
Liquor None 1.00  1.00  
 0-3 drinks per month 0.88 (0.29-2.64) 0.818 0.90 (0.28-2.89) 0.855 
 ≥ 3 drinks per week 6.21 (1.22-31.78) 0.028 7.13 (1.33-38.35) 0.022 
Personal Polyp 
History 
Yes 1.00    
No 0.47 (0.16-1.38) 0.169 0.64 (0.20-2.02) 0.446 
1st Degree Relative 
with CRC 
Yes 1.00    
No 1.89 (0.62-5.77) 0.261 1.78 (0.55-5.88) 0.337 
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Table 9: Univariate and Age-Adjusted Odds Ratios and 95% Confidence Intervals for ACF Number in relation to 
Biomarkers of Inflammation, Insulin Resistance and Lipid Levels  
 
 
Crude  Age Adjusted 
 
OR (95% CI) p-value  OR (95% CI) p-value 
IGF-2 1.01 (0.10-1.01) 0.112  1.01 (1.00-1.01) 0.117 
hsCRP 1.03 (0.91-1.16) 0.686  1.04 (.91-1.18) 0.605 
IGFBP3 1.40 (0.62-3.14) 0.421  1.46 (.62-3.42) 0.388 
IFG1 1.01 (0.99-1.04) 0.362  1.02 (.99-1.05) 0.201 
Insulin 1.31 (1.01-1.70) 0.045  1.33 (1.01-1.75) 0.039 
IL-6 1.03 (0.99-1.01) 0.561  1.00 (1.00-1.01) 0.418 
TNF-a 0.92 (0.73-1.16) 0.463  0.93 (0.73-1.18) 0.547 
Glucose 1.01 (0.98-1.03) 0.696  1.01 (0.98-1.04) 0.530 
Triglyceride 1.00 (0.98-1.02) 0.937  1.00 (0.99-1.02) 0.863 
Cholesterol, total 1.00 (0.98-1.02) 0.958  1.00 (0.98-1.02) 0.926 
Cholesterol, HDL 1.01 (0.97-1.05) 0.702  1.00 (0.96-1.04) 0.950 
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Table 10: Multivariate ORs and 95% CIs in relation to ACF Number- Base Model 
 
 
Adjusted OR 95% CI  p-value 
Statins <1 pill per week 1.00   
 ≥ 1 pill per week 1.47 0.28-7.74 0.652 
Age 1.10 0.99-1.22 0.065 
Sex Male 1.00   
 Female 0.96 0.26-3.51 0.952 
Baby Aspirin <1 pill per week 1.00   
 ≥ 1 pill per week 0.79 0.17-3.64 0.762 
All Other NSAIDs <1 pill per week 1.00   
 ≥ 1 pill per week 0.67 0.15-3.05 0.608 
1st Degree Relative with CRC Yes 1.00   
 No 1.25 0.26-6.00 0.783 
Personal History of Polyps Yes 1.00   
 No 1.08 0.26-4.43 0.915 
Smoking Never 1.00   
 Past 0.76 0.19-3.05 0.704 
 Current 4.80 0.61-37.68 0.136 
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Table 11: Multivariate ORs and 95% CIs in relation to ACF Number: - BMI added to Base Model 
 
 
Adjusted OR 95% CI  p-value 
Statins <1 pill per week 1.00   
 ≥ 1 pill per week 1.24 0.21-7.47 0.817 
Age 1.11 1.00-1.23 0.063 
Sex Male 1.00   
 Female 1.03 0.27-3.89 0.967 
Baby Aspirin <1 pill per week 1.00   
 ≥ 1 pill per week 0.73 0.15-3.55 0.694 
All Other NSAIDs <1 pill per week 1.00   
 ≥ 1 pill per week 0.69 0.15-3.14 0.627 
1st Degree Relative with CRC Yes 1.00   
 No 1.15 0.24-5.62 0.862 
Personal History of Polyps Yes 1.00   
 No 1.11 0.27-4.60 0.890 
Smoking Never 1.00   
 Past 0.85 0.20-3.54 0.817 
 Current 5.43 0.64-46.32 0.122 
BMI 1.04 0.89-1.22 0.637 
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Table 12: Multivariate ORs and 95% CIs in relation to ACF Number:  WHR added to Base Model 
 
 
Adjusted OR 95% CI  p-value 
Statins <1 pill per week 1.00   
 ≥ 1 pill per week 0.68 0.10-5.40 0.702 
Age 1.15 1.01-1.32 0.035 
Sex Male 1.00   
 Female 1.03 0.24-4.43 0.969 
Baby Aspirin <1 pill per week 1.00   
 ≥ 1 pill per week 0.98 0.18-5.40 0.984 
All Other NSAIDs <1 pill per week 1.00   
 ≥ 1 pill per week 0.93 0.19-4.58 0.931 
1st Degree Relative with CRC Yes 1.00   
 No 1.10 0.21-5.63 0.914 
Personal History of Polyps Yes 1.00   
 No 1.30 0.25-6.80 0.754 
Smoking Never 1.00   
 Past 0.66 0.11-3.92 0.648 
 Current 7.62 0.79-73.37 0.079 
Waist-Hip-Ratio 0.03 0.00-412.07 0.473 
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Table 13: Multivariate ORs and 95% CIs in relation to ACF Number: WC added to Base Model  
 
 
Adjusted OR 95% CI  p-value 
Statins <1 pill per week 1.00   
 ≥ 1 pill per week 1.20 0.20-7.36 0.842 
Age 1.12 0.99-1.26 0.062 
Sex Male 1.00   
 Female 0.91 0.23-3.59 0.893 
Baby Aspirin <1 pill per week 1.00   
 ≥ 1 pill per week 0.62 0.17-3.26 0.569 
All Other NSAIDs <1 pill per week 1.00   
 ≥ 1 pill per week 0.61 0.13-2.89 0.536 
1st Degree Relative with CRC Yes 1.00   
 No 1.24 0.25-6.22 0.793 
Personal History of Polyps Yes 1.00   
 No 0.95 0.20-4.55 0.949 
Smoking Never 1.00   
 Past 1.00 0.19-5.17 0.999 
 Current 2.58 0.54-38.54 0.162 
Waist Circumference 1.02 0.88-1.17 0.829 
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Table 14: Multivariate ORs and 95% CIs in relation to ACF Number: Age-stratified (≥50 yrs) Base Model 
 
 
Adjusted OR 95% CI  p-value 
Statins <1 pill per week 1.00   
 ≥ 1 pill per week 1.48 0.27-8.14 0.650 
Age 1.09 0.96-1.24 0.175 
Sex Male 1.00   
 Female 1.04 0.23-4.73 0.959 
Baby Aspirin <1 pill per week 1.00   
 ≥ 1 pill per week 0.99 0.19-5.01 0.986 
All Other NSAIDs <1 pill per week 1.00   
 ≥ 1 pill per week 0.64 0.13-3.06 0.638 
1st Degree Relative with CRC Yes 1.00   
 No 1.84 0.31-10.89 0.500 
Personal History of Polyps Yes 1.00   
 No 1.00 0.22-4.57 0.997 
Smoking Never 1.00   
 Past 0.69 0.17-2.90 0.615 
 Current 1.67 0.17-16.40 0.662 
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Table 15: Multivariate ORs and 95% CIs in relation to ACF Number: Age-stratified (≥50 yrs) BMI Model 
 
 
Adjusted OR 95% CI  p-value 
Statins <1 pill per week 1.00   
 ≥ 1 pill per week 1.44 0.22-9.63 0.704 
Age 1.09 0.96-1.25 0.196 
Sex Male 1.00   
 Female 1.05 0.23-4.82 0.953 
Baby Aspirin <1 pill per week 1.00   
 ≥ 1 pill per week 0.97 0.17-5.40 0.971 
All Other NSAIDs <1 pill per week 1.00   
 ≥ 1 pill per week 0.64 0.13-3.12 0.582 
1st Degree Relative with CRC Yes 1.00   
 No 1.82 0.30-11.18 0.518 
Personal History of Polyps Yes 1.00   
 No 1.00 0.22-4.66 0.997 
Smoking Never 1.00   
 Past 0.71 0.15-3.31 0.659 
 Current 1.70 0.16-18.07 0.661 
BMI 1.01 0.84-1.20 0.950 
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Table 16: Multivariate ORs and 95% CIs in relation to ACF Number: Age-stratified (≥50 yrs) WHR Model 
 
 
Adjusted OR 95% CI  p-value 
Statins <1 pill per week 1.00   
 ≥ 1 pill per week 0.55 0.06-4.80 0.591 
Age 1.19 1.00-1.41 0.054 
Sex Male 1.00   
 Female 1.03 0.19-5.53 0.970 
Baby Aspirin <1 pill per week 1.00   
 ≥ 1 pill per week 1.08 0.17-6.77 0.935 
All Other NSAIDs <1 pill per week 1.00   
 ≥ 1 pill per week 1.03 0.19-5.64 0.976 
1st Degree Relative with CRC Yes 1.00   
 No 1.76 0.27-11.5 0.554 
Personal History of Polyps Yes 1.00   
 No 1.33 0.21-8.21 0.762 
Smoking Never 1.00   
 Past 0.66 0.10-4.44 0.670 
 Current 3.30 0.25-43.07 0.363 
Waist-Hip-Ratio 0.07 .00-1760.30 0.600 
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Table 17: Multivariate ORs and 95% CIs in relation to ACF Number: Age-stratified (≥50 yrs) WC Model 
 
 
 
Adjusted OR 95% CI  p-value 
Statins <1 pill per week 1.00   
 ≥ 1 pill per week 1.18 0.17-8.00 0.869 
Age 1.13 0.96-1.32 0.133 
Sex Male 1.00   
 Female 0.87 0.18-4.29 0.865 
Baby Aspirin <1 pill per week 1.00   
 ≥ 1 pill per week 0.72 0.12-4.56 0.731 
All Other NSAIDs <1 pill per week 1.00   
 ≥ 1 pill per week 0.63 0.12-3.20 0.577 
1st Degree Relative with CRC Yes 1.00   
 No 1.87 0.30-11.75 0.507 
Personal History of Polyps Yes 1.00   
 No 0.89 0.15-5.25 0.894 
Smoking Never 1.00   
 Past 0.96 0.16-5.66 0.967 
 Current 1.63 0.15-17.40 0.685 
Waist Circumference 1.00 0.87-1.18 0.874 
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Table 18: Univariate, Age-adjusted, and Multivariate ORs and 95% CIs in relation to ACF Number: Joint Statin & Aspirin Use 
 
 
 
 Univariate Age-Adjusted1 Multivariate 
 
n Crude OR (95% CI) p-value OR (95% CI) p-value OR (95% CI)  p-value 
Statins & 
Aspirin Use 
No Statins or Aspirin 28 1.00  1.00  1.00  
Statins Only 7 15.00 (1.55-145.23) 0.019 11.03 (1.10-111.01) 0.042 2.06 (0.12-36.25) 0.620 
 Aspirin Only (baby or regular) 26 1.83 (0.59-5.68) 0.293 1.35 (0.41-4.47) 0.622 0.45 (0.08-2.57) 0.369 
 Statins and Aspirin (baby or regular) 19 4.29 (1.24-14.83) 0.022 2.26 (0.54-9.48) 0.265 0.45 (0.04-5.53) 0.535 
Age 
 80 - - 1.06 (0.99-1.13) 0.09 1.14 (1.01-1.29) 0.035 
Sex Male 39 - - - - 1.00  
 Female 18 - - - - 0.82 (0.21-3.17) 0.775 
NSAIDs2 <1 pill per week 45 - - - - 1.00  
 ≥1 pill per week 12 - - - - 0.69 (0.15-3.11) 0.627 
1st Degree 
Relative CRC 
Yes 12 - - - - 1.00  
No 45 - - - - 1.35 (0.27-6.72) 0.715 
Personal 
Polyp History 
Yes 21 - - - - 1.00  
No 36 - - - - 1.28 (0.30-5.51) 0.737 
Smoking Never 33 - - - - 1.00  
 Past 16 - - - - 0.69 (0.16-2.94) 0.616 
 Current 8 - - - - 7.30 (0.87-61.65) 0.068 
1 See Table 10 for age-adjusted analyses for sex, NSAIDs, 1st Degree Relative with CRC, Personal Polyp History, and Smoking 
2
 Removing NSAIDs from the analysis did not significantly affect results.   
 
 
 
 
 
